Is the Immutep (IMMP) investment thesis intact?

It is under pressure. Readouts currently rates the Immutep Thesis Challenged. Efti reset still depends on manufacturing explanation and funded head and neck trials.

What is the next catalyst for Immutep (IMMP)?

The next dated event is Phase 1 results for IMP761, on Nov 10, 2026, as stated by the company.

IMMPImmutep Limited

Market reactionShares rose 24% on Nov 6.

ChallengedLast material event Sep 11, 2026 · Updated Oct 30, 2026

Efti reset still depends on manufacturing explanation and funded head and neck trials

Immutep develops immunotherapies based on the LAG-3 protein; its lead drug, eftilagimod alfa (efti), is being refocused on head and neck cancer and soft tissue sarcoma, and none of its products is approved.

Immutep's efti case centers on head and neck cancer and neoadjuvant soft tissue sarcoma after TACTI-004 ended. Manufacturing differences offer a possible explanation, but the root cause analysis remains unfinished. A new 200 L run is contracted; trial starts targeted for H2 CY27 depend on design, regulators, manufacturing, partnering and resources. IMP761 is now a co-priority, supported by healthy-volunteer data. Cash has declined, with a subsequent French rebate supporting development; management still expects runway well into H1 of CY28.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

A head and neck cancer trial starts with 200 L eftiAwaiting evidenceFinal head and neck trial design, funding arrangements and start, targeted for H2 CY27.Next: Final head and neck trial design, funding arrangements and start, targeted for H2 CY27.

Why it is in this state

The evidence, what would weaken it and the source filing

The root cause analysis confirms the manufacturing explanationAwaiting evidenceAGM root cause update on 27 November 2026, looking for a causal link between manufacturing differences and the clinical outcome.Next: AGM root cause update on 27 November 2026, looking for a causal link between manufacturing differences and the clinical outcome.

Why it is in this state

The evidence, what would weaken it and the source filing

IMP761 moves into patients with autoimmune diseaseAwaiting evidenceACR data on 10 November 2026, followed by a defined plan for autoimmune patient development.Next: ACR data on 10 November 2026, followed by a defined plan for autoimmune patient development.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts well into the first half of 2028SupportedNext cash report and trial budgets showing whether planned efti and IMP761 development remains affordable.Next: Next cash report and trial budgets showing whether planned efti and IMP761 development remains affordable.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Does the manufacturing explanation justify renewed efti development?

Tests: The root cause analysis confirms the manufacturing explanation

Root cause update at the AGM on 27 November 2026.

Can Immutep link the manufacturing differences to TACTI-004's outcome and explain why returning to smaller-scale material addresses the problem?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical

+12.1%Sep 11, 2026

Efti reset still depends on manufacturing explanation and funded head and neck trials

BrokenClinical

-82.6%Mar 16, 2026

TACTI-004 Phase III futility analysis — trial discontinued

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Head and neck squamous cell carcinoma· first line · CPS <1

Eftilagimod alfa · 1 upcoming · 1 completed

Study Initiation

H2 2027

Autoimmune disease

IMP761 · 1 upcoming · 2 completed

Phase 1 Data

November 10, 2026

Soft tissue sarcoma· resectable · neoadjuvant

Eftilagimod alfa · 1 upcoming · 2 completed

Study Initiation

H2 2027

Non-small cell lung cancer· first line · advanced/metastatic

Eftilagimod alfa · 1 completed

Phase 3 Data: InterimTACTI-004Discontinued

Mar 13, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Immutep (IMMP) investment thesis intact?: It is under pressure. Readouts currently rates the Immutep Thesis Challenged. Efti reset still depends on manufacturing explanation and funded head and neck trials.
What is the next catalyst for Immutep (IMMP)?: The next dated event is Phase 1 results for IMP761, on Nov 10, 2026, as stated by the company.

Other companies we cover in these diseases

Head and neck squamous cell carcinoma: Coherus Oncology (CHRS)Pyxis Oncology (PYXS)
Non-small cell lung cancer: Compass Therapeutics (CMPX)Summit Therapeutics (SMMT)

Disease areas: Lung cancer, Breast and gynecologic cancers, Other cancers, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

6 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.